![]() |
|
|
Vol. 295, Issue 3, 1005-1011, December 2000
Second Tokushima Institute of New Drug Research, Otsuka
Pharmaceutical Co. Ltd., Kagasuno Kawauchi-cho, Tokushima, Japan
OPC-51803 is the first nonpeptide vasopressin (AVP)
V2-receptor-selective agonist. Its pharmacological profile,
including antidiuretic action and receptor binding, was characterized
using conscious Brattleboro rats with hereditary diabetes insipidus and
Sprague-Dawley rats. In membrane preparations from the liver and
kidney, OPC-51803 displaced the [3H]AVP binding to
V2-receptors (Ki = 49.8 ± 8.1 nM) more greatly than that to
V1a-receptors (Ki = 1061 ± 60 nM), showing a 21 times higher affinity for
V2-receptors. At single oral doses of 0.003 to 0.3 mg/kg in
female Brattleboro rats, OPC-51803 decreased urine volume (from
10.8 ± 1.1 to 0.5 ± 0.2 ml during 0-2 h postdosing) and
increased urinary osmolality (from 114 ± 9 to 432 ± 114 mOsm/kg) in a dose-dependent manner. During the period of 4-week
treatment with OPC-51803, significant and constant antidiuresis was
observed. In male Sprague-Dawley rats with normal plasma AVP levels,
OPC-51803 at 0.03 to 0.3 mg/kg also produced a dose-dependent
antidiuretic action (urine volume: from 2.6 ± 0.6 to 1.1 ± 0.2 ml at 0-4 h postdosing). Few changes in urinary parameters, serum
parameters, or plasma hormone levels were observed. OPC-51803 did not
change blood pressure or heart rate, or inhibit AVP-induced pressor
response even at 30 mg/kg p.o. These results demonstrate that OPC-51803 is a V2-selective agonist that produces a significant
antidiuretic action after single and multiple oral dosing in
AVP-deficient and normal AVP states. The data suggest that OPC-51803 is
a useful therapeutic drug in the treatment of hypothalamic diabetes
insipidus, nocturnal enuresis, and some kinds of urinary incontinence.